PubMed

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis.

Kulasingam SL, Benard S, Barnabas RV, Largeron N, Myers ER.

Cost Eff Resour Alloc. 2008 Feb 15;6:4.PMID: 18279515 [PubMed - in process]Related articlesFree article

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

Annemans L, Rémy V, Oyee J, Largeron N.

Pharmacoeconomics. 2009;27(3):231-45. doi: 10.2165/00019053-200927030-00006.PMID: 19354343 [PubMed - indexed for MEDLINE]Related articles

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G.

Sex Health. 2007 Sep;4(3):165-75.PMID: 17931529 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.

Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S.

Curr Med Res Opin. 2008 May;24(5):1473-83. Epub 2008 Apr 14.PMID: 18413014 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.

Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V.

Int J Technol Assess Health Care. 2008 Winter;24(1):10-9.PMID: 18218164 [PubMed - indexed for MEDLINE]Related articles

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.

Dasbach EJ, Insinga RP, Elbasha EH.

BJOG. 2008 Jul;115(8):947-56. Epub 2008 May 22.PMID: 18503574 [PubMed - indexed for MEDLINE]Related articles

A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme.

Dee A, Howell F.

Eur J Public Health. 2009 Nov 11. [Epub ahead of print]PMID: 19864366 [PubMed - as supplied by publisher]Related articles

Health and economic implications of HPV vaccination in the United States.

Kim JJ, Goldie SJ.

N Engl J Med. 2008 Aug 21;359(8):821-32.PMID: 18716299 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.

Kim JJ, Goldie SJ.

BMJ. 2009 Oct 8;339:b3884. doi: 10.1136/bmj.b3884.PMID: 19815582 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

de Kok IM, van Ballegooijen M, Habbema JD.

J Natl Cancer Inst. 2009 Aug 5;101(15):1083-92. Epub 2009 Jul 1.PMID: 19571256 [PubMed - indexed for MEDLINE]Related articles

The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.

Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH.

J Med Econ. 2010 Mar;13(1):110-8.PMID: 20085477 [PubMed - in process]Related articles

The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.

Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, Elbasha EH.

Asian Pac J Cancer Prev. 2008 Jul-Sep;9(3):459-66.PMID: 18990021 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.

Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E.

Arch Med Res. 2009 Aug;40(6):503-13.PMID: 19853192 [PubMed - in process]Related articles

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.

Kim JJ, Ortendahl J, Goldie SJ.

Ann Intern Med. 2009 Oct 20;151(8):538-45.PMID: 19841455 [PubMed - indexed for MEDLINE]Related articles

Health and economic impact associated with a quadrivalent HPV vaccine in Italy.

Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N.

Gynecol Oncol. 2009 Feb;112(2):370-6. Epub 2008 Nov 28.PMID: 19041125 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan.

Liu PH, Hu FC, Lee PI, Chow SN, Huang CW, Wang JD.

BMC Health Serv Res. 2010 Jan 11;10:11.PMID: 20064239 [PubMed - in process]Related articlesFree article

The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.

Sinanovic E, Moodley J, Barone MA, Mall S, Cleary S, Harries J.

Vaccine. 2009 Oct 19;27(44):6196-202. Epub 2009 Aug 19.PMID: 19698807 [PubMed - indexed for MEDLINE]Related articles

Age-Based Programs for Vaccination against HPV.

Elbasha EH, Dasbach EJ, Insinga RP, Haupt RM, Barr E.

Value Health. 2009 Mar 10. [Epub ahead of print]PMID: 19490561 [PubMed - as supplied by publisher]Related articles

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.

Brisson M, Van de Velde N, De Wals P, Boily MC.

Vaccine. 2007 Jul 20;25(29):5399-408. Epub 2007 May 22.PMID: 17561316 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.

Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ.

J Natl Cancer Inst. 2008 Mar 5;100(5):308-20. Epub 2008 Feb 26.PMID: 18314477 [PubMed - indexed for MEDLINE]Related articlesFree article